# Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach

> **NCT02553915** · PHASE2,PHASE3 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 61 (actual)

## Conditions studied

- Major Depressive Disorder
- Overweight
- Inflammation

## Interventions

- **OTHER:** Placebo
- **DRUG:** EPA 1 g/day
- **DRUG:** EPA 2 g/day
- **DRUG:** EPA 4 g/day

## Key facts

- **NCT ID:** NCT02553915
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-07-13
- **Final completion:** 2022-03-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553915, "Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02553915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*